Congress funds HPV cancer prevention push, targeting vaccine gaps in underserved communities

What it does

This bill directs the CDC to run a national public awareness campaign about HPV vaccination and cancer prevention, funded at $5 million per year through 2030. It also increases funding for the Breast and Cervical Cancer Early Detection Program to $300 million annually through 2030. The campaign will target undervaccinated communities, combat vaccine misinformation, and work with health providers, schools, nonprofits, and state/local health departments to boost HPV vaccination rates and early cancer screening.

Why we flagged it

The bill's operative mechanism is a federally funded public awareness campaign and screening program expansion, both directed at cancer prevention and health equity. It is a straightforward public health appropriation with no private carve-outs or immunity provisions.

What the text implies

• Campaign grants to nonprofit entities may create indirect benefit to vaccine manufacturers through increased demand, though the bill does not name or favor any specific company.
• Expansion of the Breast and Cervical Cancer Early Detection Program may increase screening volume, potentially benefiting diagnostic and treatment providers, but the primary intent is public health access.
• The bill's focus on health provider recommendations as a driver of vaccination may shift some burden of vaccine promotion onto clinical staff, potentially affecting provider workload and liability perception.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill funds a public health campaign addressing a documented cancer prevention gap, with particular attention to disparities affecting Black and Hispanic women and rural communities. It expands access to cervical cancer screening and vaccination information without restricting citizen rights or creating new barriers to care.

Who stands to gain

• nonprofit organizations (campaign contractors)
• vaccine manufacturers (indirect demand increase)
• diagnostic and treatment providers (screening expansion)

Named in the bill

CDC (Centers for Disease Control and Prevention), HHS (Department of Health and Human Services), National Academy of Medicine, State and local public health departments, Nonprofit organizations, Pfizer (PFE), Bristol Myers Squibb (BMY), Johnson & Johnson (JNJ), Gilead Sciences (GH), DaVita (DVA)

Where it stands

8 cosponsors: 6 Democrats, 2 Republicans.

• Dec 10, 2025 — Introduced · Congress.gov: “Introduced in House”
• Dec 10, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

4 lobbying clients named this bill on 5 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $963,780 in lobbying spend. A filing names 12 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 72% of bills with at least one filing.

Kathy Castor, the sponsor, reported $1,028,281 in PAC receipts in the 2026 cycle.

• American Dental Association — $593,780 on 2 filings
• American Academy of Pediatrics — $320,000 on 1 filing
• Infectious Diseases Society of America — $50,000 on 1 filing
• Vaccinate Your Family — $0 on 1 filing

Lobbying Disclosure Act filings through Jul 16, 2026. A filing shows who paid to lobby on a bill it names, not what changed.